Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 5/20 | 0.52 |
| ▸ | AKT3 | Q9Y243 | 10/20 | 0.51 |
| ▸ | CHUK | O15111 | 2/20 | 0.49 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.49 |
| ▸ | DKK1 | O94907 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423214 | 0.87 | AKT3 (0.55) | IKBKBAKT3CHUKIKBKGCAMK2D | |
| SCHEMBL12423209 | 0.86 | AKT3 (0.56) | IKBKBAKT3CHUKIKBKGDKK1 | |
| SCHEMBL12423200 | 0.86 | AKT3 (0.61) | IKBKBAKT3CHUKIKBKGSTAT6 | |
| SCHEMBL14100239 | 0.85 | IKBKB (0.47) | IKBKBAKT3CHUKIKBKGSYK | |
| SCHEMBL5069822 | 0.83 | IKBKB (0.54) | IKBKBAKT3CHUKIKBKGDKK1 | |
| SCHEMBL12423220 | 0.83 | AKT3 (0.51) | IKBKBAKT3CHUKIKBKGSTAT6 | |
| SCHEMBL12423188 | 0.82 | IKBKB (0.47) | IKBKBAKT3CHUKIKBKGDKK1 | |
| SCHEMBL2195564 | 0.78 | MKNK1 (0.56) | IKBKBCHUKIKBKGGSK3BCAMK2D | |
| SCHEMBL12423426 | 0.78 | IKBKB (0.48) | IKBKBAKT3CHUKIKBKGDKK1 | |
| SCHEMBL5000430 | 0.77 | AKT3 (0.75) | IKBKBAKT3CHUKIKBKG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977481-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977481-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | ARNOLD WILLIAM D | 2010-12-02 | — | — | US | disclosed |
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | ARNOLD WILLIAM D | 2010-12-02 | — | — | US | disclosed |
| US-7803806-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803806-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2007053776-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | MAP3K20, MAP3K6, MAP4K2 | IKBKB 553/4885AKT3 340/4885CHUK 164/4885 |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | MAP3K20, MAP3K6, MAP4K2 | IKBKB 553/4885AKT3 340/4885CHUK 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.